PO.TB04.06 · 肿瘤生物学
将患者来源的肿瘤模型整合入转化肿瘤学和药物发现
Integrating patient-derived tumor models into translational oncology and drug discovery
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
患者来源的肿瘤模型为在临床相关背景下研究癌症生物学和治疗反应提供了强大工具。Dana-Farber癌症研究所的患者来源模型中心（CPDM）是一个协作研究枢纽，专注于患者来源异种移植（PDX）、患者来源细胞系（PDCL）以及类器官/球体培养物的生成、表征和应用，以加速转化肿瘤学。CPDM与学术界和产业界研究人员合作，助力数据驱动的药物发现、临床前验证和功能性精准医学。该中心维护着一个庞大的患者来源模型库，涵盖脑肿瘤、血液系统恶性肿瘤以及各种实体瘤，每个模型均标注有相应的临床和基因组数据。这些模型面向全球合作者开放，以推进转化和精准肿瘤学研究。为支持精准肿瘤学和临床前研究，CPDM已建立自动化成像流程和标准化定量检测，用于在2D和3D培养系统中实时监测生长和药物反应。此外，该中心的功能性精准医学（FPM）平台整合了活细胞成像和患者特异性药物筛选，为治疗选择提供依据并提高转化预测的准确性。这些努力共同将CPDM定位为连接临床前建模与临床应用的转化桥梁，促进数据驱动的合作，推进个性化癌症治疗。
查看英文原文 English abstract
Patient-derived tumor models provide powerful tools to investigate cancer biology and therapeutic responses in clinically relevant contexts. The Center for Patient-Derived Models (CPDM) at the Dana-Farber Cancer Institute is a collaborative research hub specializing in the generation, characterization, and application of patient-derived xenografts (PDX), patient-derived cell lines (PDCLs), and organoid/spheroid cultures to accelerate translational oncology. CPDM partners with both academic and industry researchers to enable data-driven drug discovery, preclinical validation, and functional precision medicine. The center maintains an extensive repository of patient-derived models spanning brain tumors, hematologic malignancies, and a broad range of solid tumors, each annotated with corresponding clinical and genomic data. These models are available to collaborators worldwide to advance translational and precision oncology research. To support precision oncology and preclinical research, CPDM has established automated imaging pipelines and standardized quantitative assays for real-time monitoring of growth and drug response in both 2D and 3D culture systems. In addition, the center's Functional Precision Medicine (FPM) platform integrates live-cell imaging and patient-specific drug screening to inform therapeutic selection and improve translational predictive accuracy. Together, these efforts position CPDM as a translational bridge between preclinical modeling and clinical application, facilitating data-driven collaborations that advance personalized cancer treatment.
利益披露 Disclosure
U. Khalid, None..
T. Quinn, None..
C. Fu, None..
L. Loosbrock, None..
A. Panigrahy, None..
A. Shetty, None.
K. Ligon,
Bristol Myers Squibb Independent Contractor, ).
Servier Pharmaceuticals Independent Contractor.
Blaze Biosciences Independent Contractor.
Integragen Independent Contractor.
Lilly ).
Travera g., Board of Directors, non-salaried role), Independent Contractor, Stock, Other Business Ownership.
S. Bhatia, None.